Connective-Tissue Arteriopathies and Other Rare Nonatherosclerotic Arterial Disorders

51.1Definition and presentation

Inherited connective-tissue arteriopathies present with thoracic aortic aneurysms or dissections at unusually young ages, often accompanied by syndromic features, uncommon arterial territory involvement, or a family history of vascular events ACC/AHA 2022. The presentation and natural history depend on the specific syndrome and pathogenic variant:

• Marfan syndrome (FBN1 variant): Characterized by aortic-root dilation, mitral valve prolapse, and skeletal habitus.
• Loeys-Dietz syndrome (TGFBR1, TGFBR2, TGFB2, TGFB3 variants): Characterized by aggressive dissection risk at smaller diameters than Marfan syndrome.
• Vascular Ehlers-Danlos syndrome (vEDS, pathogenic COL3A1 variant): Characterized by tissue fragility and arterial dissection, aneurysm, or rupture, often involving medium-sized arteries. Arterial lesions may remain clinically silent until a complication occurs vEDS Imaging 2022.
• Aneurysms-osteoarthritis syndrome (SMAD3 variant): Characterized by familial thoracic aortic aneurysm paired with early-onset osteoarthritis ACC/AHA 2022 · SMAD3 Cohort 2011.
• Smooth-muscle dysfunction (ACTA2 variant): The single most common gene in heritable thoracic aortic disease, characterized by premature stroke and coronary artery disease with moyamoya-like cerebrovascular changes.
• Familial thoracic aortic aneurysm (MYH11 variant): Characterized by a patent ductus arteriosus association.

51.2Genetic diagnosis and phenotyping

Targeted genetic testing is central to evaluation for patients presenting with thoracic aortic aneurysm at a young age or with a positive family history ACC/AHA 2022. A confirmed gene-level diagnosis establishes the surgical threshold, the territories requiring imaging, and the dissection risk. Offer genetic counseling and cascade testing for a familial pathogenic or likely pathogenic variant. For Marfan, Loeys-Dietz, and other heritable thoracic aortic disease, carriers require gene-specific aortic surveillance. First-degree relatives of a patient with thoracic aortic disease still need screening aortic imaging when testing is negative or yields only a variant of uncertain significance; the absence of an identified causal variant does not exclude familial disease. For familial vEDS, COL3A1 testing identifies relatives needing the syndrome-specific arterial surveillance described below; aortic-root imaging alone does not cover its predominantly medium-artery phenotype vEDS Imaging 2022.

Variant classification expresses the strength of evidence that a variant causes disease; it is not a scale of clinical severity. A missense variant of uncertain significance must not be treated as a proven milder Marfan genotype or used by itself to set an operative threshold or assign relatives to a pathogenic-variant cascade. Apply the ClinGen FBN1-specific interpretation framework, integrate the phenotype and family history, and seek re-evaluation through clinical genetics as evidence changes ACC/AHA 2022 · FBN1 Consensus 2024.

51.3Diagnosis and surveillance

Surveillance combines local and systemic imaging based on the genotype. In Marfan syndrome, echocardiography monitors aortic-root diameter and mitral valve morphology, while cross-sectional computed tomography angiography (CTA) or magnetic resonance angiography (MRA) maps the entire aorta to detect distal disease ACC/AHA 2022 · Cornell Aortic Registry 2025. After a new Marfan diagnosis, obtain a baseline echocardiogram, repeat at 6 months to establish the growth rate, then image annually if the root is stable and well below threshold. Move to every 6 months or shorter once the diameter reaches 4.5 cm, approaches the operative threshold, or grows rapidly. Obtain whole-aorta CTA or MRA at baseline and periodically to cover segments echocardiography cannot see. A higher prevalence of unruptured intracranial aneurysms in Marfan syndrome supports one-time intracranial screening, with subsequent rupture-risk decisions following standard intracranial criteria Marfan Intracranial 2023.

In vascular Ehlers-Danlos syndrome, widespread and clinically silent arterial lesions (aneurysms, dissections, fistulae) support baseline and periodic head-to-pelvis arterial imaging vEDS Imaging 2022.

51.4Medical therapy

Medical therapy slows arterial dilation but does not eliminate event risk or replace the need for surveillance and prophylactic surgery.

In Marfan syndrome, both angiotensin receptor blockers (ARBs) and beta-blockers slow aortic-root growth. Individual-patient-data meta-analysis supports both agents, with combination therapy providing additive benefit in some subgroups when tolerated Marfan Medical IPD 2022. Trial evidence supports an ARB class effect across age groups COMPARE 2020 · AIMS 2019. The pediatric trial framework establishes losartan and atenolol as standard agents for childhood-onset disease Pediatric Marfan Cohort 2013 · Pediatric Marfan RCT 2007.

In vascular Ehlers-Danlos syndrome, celiprolol is used as a medical-risk modifier to reduce arterial event rates, although regional availability varies Dutch vEDS Cohort 2024 · UK vEDS Registry 2023.

51.5Intervention thresholds and surgical decision-making

The decision to intervene balances the natural history of the specific genetic variant against procedural risk. In connective-tissue arteriopathy, surgical indications follow gene-specific thresholds rather than sporadic aneurysm criteria.

For descending thoracic and thoraco-abdominal disease, ESVS 2026 adds territory-specific guidance: specialist multidisciplinary care for genetic aortopathy is recommended (I C), and open repair should generally be preferred for elective thoracic repair (IIa C). This does not replace the ACC/AHA aortic-root thresholds below or create a universal diameter threshold for vEDS ESVS 2026.

The operative pathway requires structured decision-making:

1. Establish the gene-specific phenotype to define surgical thresholds and arterial territories at risk.
2. Decide surveillance versus prophylactic repair based on established diameter thresholds, confirmed growth rates, and family history.
3. For elective repair in Marfan and Loeys-Dietz syndromes, select valve-sparing root replacement in eligible candidates or composite valve-graft replacement based on valve morphology and center experience Marfan Root Surgery 2019. Open valve-sparing or composite aortic root replacement is the standard elective operation; thoracic endovascular aortic repair (TEVAR) is generally avoided in the native connective-tissue aorta and reserved for selected distal or dissection scenarios or as a bridge to definitive open reconstruction ACC/AHA 2022.
4. In vEDS, tissue fragility increases procedural risk. For descending thoracic pathology, choose observation or intervention through individualized specialist assessment rather than a categorical prohibition of elective repair ESVS 2026.
5. In life- or limb-threatening emergencies, prioritize the least anatomically ambitious operation that secures immediate hemorrhage or ischemia control, anticipating access complications and suture-line failure ACC/AHA 2022 · UK vEDS Registry 2023.

51.6Special populations

Pregnancy in vascular Ehlers-Danlos syndrome carries a materially increased risk of arterial and uterine rupture. Management requires preconception counseling and tertiary-care coordination among maternal-fetal medicine, anesthesia, and vascular surgery. Routine elective arterial intervention is avoided during pregnancy unless a life-threatening indication emerges vEDS Pregnancy 2026 · UK vEDS Registry 2023.

Pediatric vascular Ehlers-Danlos syndrome requires early diagnosis to facilitate activity modification, sport guidance, and connection to a specialist pathway prior to the first arterial event Pediatric vEDS 2025 · UK vEDS Registry 2023.

Quality of life is reduced in Marfan syndrome, driven substantially by prior aortic intervention and musculoskeletal involvement. These factors directly affect recovery expectations and surveillance adherence GenTAC 2017.

In women with Marfan syndrome contemplating pregnancy, prophylactic aortic root or ascending replacement before conception is reasonable at a diameter >= 4.5 cm. Dissection risk rises materially once the aorta exceeds ~4.0 cm, so counsel before pregnancy, maintain strict beta-blockade, and follow with serial echocardiography through pregnancy and the postpartum period ACC/AHA 2022.

51.7Areas of controversy

Aortic biomechanical properties, including stiffness and strain, and advanced three-dimensional imaging are under investigation as early markers of Marfan aortic dilation but remain research-stage metrics rather than established surgical triggers Marfan Biomechanics 2024. Novel pharmacologic adjuncts, such as resveratrol, lack validated clinical endpoints and are not part of routine therapy outside trial settings Resveratrol Marfan 2024. Gene-specific surgical thresholds for Loeys-Dietz syndrome continue to evolve as new genotype-phenotype correlations emerge Heritable TAD 2023. In asymptomatic vascular Ehlers-Danlos syndrome, the optimal interval for head-to-pelvis surveillance imaging is not standardized and relies on center-level expertise vEDS Imaging 2022.

Further reading

• Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. (2022). Marfan ARB/beta-blocker individual-patient trial synthesis; not applicable to all connective-tissue arteriopathies. Marfan Medical IPD 2022